CMB International: Maintaining the Chinese Pharmaceutical Industry's “Superior to Market” Health Insurance Dual Catalogue and Continuing to Support Innovative Drugs

Zhitongcaijing · 1d ago

The Zhitong Finance App learned that CMB International released a research report stating that the 2026 edition of the basic medical insurance and commercial insurance catalogue will continue to support innovative drugs and maintain the Chinese pharmaceutical industry's “superior to the market” rating.

The bank pointed out that the MSCI China Healthcare Index has accumulated a cumulative increase of 14.8% since 2026, outperforming the MSCI China Index by 32%. The scale of BD transactions for innovative drugs overseas is growing rapidly. According to the State Drug Administration, the total amount of foreign authorized transactions of China's innovative drugs in the first three quarters of this year was about 130 billion US dollars, which is close to the level of the full year of 2025.

The bank believes that the value of innovative drugs going overseas will be realized by future milestone payments and sales shares. Currently, the total potential milestones of major innovative pharmaceutical companies in Hong Kong stock, excluding sales shares, have reached an average of about 2.3 times the market value; as the value of authorized varieties is realized, the company's valuation has room for a significant increase.

In addition, CXO also ushered in a boom in demand. Global CXOs generally raised their annual revenue guidelines in the second and third quarters of this year. The bank believes that CXO companies have high growth certainty, and that strong order growth and price increases will continue to drive performance until next year. Considering the strong implementation of innovative drugs and CXO fundamentals, the bank believes that the pharmaceutical industry's valuation repair market is expected to continue.

The bank said that 107 new drugs were added to the catalogue adjustment. Of these, 51 were Class 1 innovative drugs, a record high. At the same time, 34 types were transferred to focus on including innovative drugs with clear clinical benefits and excellent economic evaluations. 12 new innovative drugs have been added to the commercial insurance innovative drug catalogue, including gene therapy, solid tumor CAR-T, nuclear drugs, etc.

Key innovative products from many companies have been included, including Maxidu Peptide and Pikonqibimab from Cinda Biotech (01801), Bodutrazumab and lucansatuzumab related indications from Colenbott Biological-B (06990), recontrastuzumab and darcili-related indications from Hengrui Pharmaceuticals (01276), and Tetacept prefilled needles from Rongchang Biotech (09995).

The bank recommended purchasing Pharma Ming Kangde (603259.SH), Pharmaceutical (02269), Yingyan Biotech (09606), Sansheng Pharmaceuticals (01530) and Cinda Biotech. The target prices were RMB 190, HK$60, HK$284.5, HK$34.78 and HK$138.63, respectively.